Nektar Therapeutics (NKTR)
NASDAQ:NKTR
NKTR Stock Chart & Stats
$70.97
-$0.04(-3.36%)
At close: 4:00 PM EST
$70.97
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$6.49 - $77.97
Previous CloseN/A
Volume706.47K
Average Volume (3M)1.21M
Market Cap
$2.04B
Enterprise Value$1.57B
Total Cash (Recent Filing)$245.75M
Total Debt (Recent Filing)$148.91M
Price to Earnings (P/E)―
Beta3.78
Next Earnings
May 07, 2026EPS Estimate
-1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding28,687,963
10 Day Avg. Volume777,786
30 Day Avg. Volume1,205,779
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue28.50
Enterprise Value/Gross Profit28.60
Enterprise Value/Ebitda-12.80
Forecast
1Y Price Target
$127.33Price Target Upside79.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-10.1
Revenue Forecast (FY)$41.23M
Bulls Say, Bears Say
Bulls Say
Alopecia Areata Clinical ReadoutAn extension readout from the REZOLVE-AA trial could show sustained or deepening hair-regrowth responses, which would strengthen approval prospects and materially expand the drug's commercial opportunity in alopecia areata.
Clinical Differentiation And Dosing ConvenienceMid‑stage data showing efficacy comparable to a leading IL‑4/13 therapy, combined with a lower injection burden and a favorable safety profile, could position the drug as a preferred second‑line option and help it compete commercially.
Phase 3 Initiation And Regulatory AlignmentPlanned Phase 3 trials in atopic dermatitis and stated intent to align with regulators on a registrational path for alopecia areata signal clear development momentum and increase the likelihood of a defined path to market.
Bears Say
Clinical Timeline UncertaintyRefined timing for several trial readouts and extensions introduces uncertainty around the pace of clinical progress and raises execution risk for upcoming catalysts.
Commercial CompetitionStrong incumbent first‑line therapies create significant competitive pressure that may limit market share gains and challenge commercial adoption of the drug.
Financial Performance RiskOngoing unprofitability despite revenue outperformance represents a financial risk that could pressure the stock if a path to sustainable profitability is not established.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $6.49 and its highest was $77.97 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.04B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Mar 12, 2026. The company reported -$1.78 earnings per share for the quarter, beating the consensus estimate of -$2.474 by $0.694.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.77.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 28,687,963 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.78 in its last earnings report, beating expectations of -$2.474. Following the earnings report the stock price went up 4.107%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.33 (79.41% Upside)
$127.33 (79.41% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 945.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
473.93%
12-Months-Change
Fundamentals
Return on Equity
-399.10%
Trailing 12-Months
Asset Growth
-7.72%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive clinical and strategic narrative: Respag delivered compelling Phase 2b results with durable efficacy, deepening responses (including up to a fivefold increase in EASI-100), a sizable safety database (>1,000 patients; ~381 patient-years), and FDA alignment to proceed to phase 3 (first randomization in June 2026). The company also strengthened its balance sheet with ~ $476M raised since year-end, enabling phase 3 investments. Offsetting factors include substantial ongoing losses (2025 net loss $164.1M), a sharp projected increase in R&D spend in 2026 (guidance $200M–$250M), rising non-cash interest expense, some safety/tolerability signals (ISRs), pending litigation, and multi-year timelines to approval, creating execution and cash-burn risk. On balance, the positive clinical progress and recent financings meaningfully outweigh the near-term financial and execution risks, but investors should monitor phase 3 execution, 2026 burn, and upcoming 52-week AA data and other catalysts.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$127.33
▲(79.41% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
3.71% Insiders
7.41% Mutual Funds
30.50% Other Institutional Investors
53.35% Public Companies and Individual Investors